8-K: LENSAR Q3 Revenue Up 6%, Alcon Merger Delayed to Q1 2026

LENSAR reported a 6% revenue increase in Q3 2025 driven by procedure volume, but its acquisition by Alcon is now expected to close in Q1 2026, later than anticipated.

Summary

• Total revenue for the third quarter ended September 30, 2025, was $14.3 million, an increase of 6% compared to $13.5 million in the same period of 2024.
• Worldwide procedure volume increased by approximately 11% in Q3 2025 as compared to Q3 2024.
• 18 ALLY Robotic Cataract Laser Systems were placed in Q3 2025, growing the ALLY installed base by 77% to approximately 185 systems over September 30, 2024.
• The total combined installed base of LENSAR Laser Systems and ALLY Systems increased by 20% to approximately 425 systems as of September 30, 2025.
• Net loss for Q3 2025 was $3.7 million, or ($0.31) per common share, compared to a net loss of $1.5 million, or ($0.13) per common share, in Q3 2024, primarily due to acquisition-related costs.
• Selling, general and administrative expenses increased by 98% to $12.0 million, including approximately $5.3 million in acquisition-related costs related to the proposed merger with Alcon.
• The pending acquisition by Alcon is now expected to close in the first quarter of 2026, following a request for additional information from the U.S. Federal Trade Commission.
• Cash, cash equivalents, and investments totaled $16.9 million as of September 30, 2025, a decrease from $22.5 million at December 31, 2024.

Sentiment

Score: 4

Explanation: While revenue and installed base growth are positive, the significant increase in net loss, negative EBITDA, declining cash balance, and the delay in the Alcon acquisition create considerable uncertainty and financial strain. The negative equity position is also a concern.

Positives

• Total revenue increased by 6% to $14.3 million in Q3 2025 compared to Q3 2024.
• Worldwide procedure volume grew by approximately 11% in Q3 2025 year-over-year.
• The ALLY installed base increased by 77% to approximately 185 systems as of September 30, 2025.
• The total combined laser installed base grew by 20% to approximately 425 systems as of September 30, 2025.
• Recurring revenue increased to $10.77 million in Q3 2025 from $9.88 million in Q3 2024, representing 75% of total revenue.

Negatives

• Net loss significantly increased to $3.7 million, or ($0.31) per common share, in Q3 2025 from $1.5 million, or ($0.13) per common share, in Q3 2024.
• Selling, general and administrative expenses increased by 98% to $12.0 million, largely due to $5.3 million in acquisition-related costs.
• EBITDA was ($2.7) million in Q3 2025, a decrease from ($0.6) million in Q3 2024.
• Adjusted EBITDA was ($0.3) million in Q3 2025, down from $0.4 million in Q3 2024.
• Cash, cash equivalents, and investments decreased to $16.9 million as of September 30, 2025, from $22.5 million at December 31, 2024, with a $3.4 million decrease in Q3 2025 alone.
• The expected closing of the Alcon acquisition has been delayed to Q1 2026.
• Total stockholders (deficit) equity moved from $4.862 million at December 31, 2024, to ($25.907) million at September 30, 2025.

Risks

• The proposed merger with Alcon may not be completed in a timely manner or at all, including risks related to regulatory approvals being delayed or subject to unanticipated conditions.
• Failure to realize the anticipated benefits of the proposed merger.
• The possibility of competing offers or acquisition proposals for the Company.
• Risks that the milestone related to the contingent value right (CVR) is not achieved.
• The possibility that any or all conditions to the consummation of the merger may not be satisfied or waived.
• The occurrence of any event that could lead to the termination of the merger, potentially requiring LENSAR to pay a termination fee or other expenses.
• The effect of the announcement or pendency of the merger on the Company's ability to retain and hire key personnel, or its operating results and business generally.
• Potential for unknown, probable, or estimable liabilities related to the merger or unexpected costs, charges, or expenses.
• Diversion of management's time and attention to issues relating to the merger.
• Significant transaction costs in connection with the merger.
• Adverse consequences of legal proceedings instituted against the Company following the announcement of the merger.
• The Company's stock price may decline significantly if the merger is not consummated.

Future Outlook

The acquisition by Alcon is now expected to close in the first quarter of 2026, following a request for additional information from the U.S. Federal Trade Commission. The company will not be hosting an earnings conference call this quarter due to the pending acquisition.

Management Comments

• "We are pleased with the continued adoption of ALLY both in the U.S. and abroad, as well as the continuous, positive feedback from surgeons reinforcing ALLYs compelling value proposition."
• "We grew the ALLY installed base significantly over the past 12 months and achieved solid growth in procedure volume compared to the third quarter of 2024."
• "We continue to deliver increased value to our surgeon partners through higher efficiencies and excellent patient outcomes."
• "In association with our pending acquisition by Alcon, we continue to work collaboratively with the U.S. Federal Trade Commission, responding to its request for additional information, and now expect the transaction to close in the first quarter of 2026."

Industry Context

LENSAR operates in the competitive medical technology sector, specifically focusing on advanced robotic laser solutions for cataract treatment. The continued adoption and growth of its ALLY system's installed base and procedure volume suggest a positive market reception for its innovative technology, aligning with a broader trend towards precision and efficiency in surgical procedures. The pending acquisition by Alcon, a global leader in eye care, indicates a consolidation trend and potential for LENSAR's technology to gain wider market penetration under a larger entity, despite the current regulatory delay.

Legal Proceedings

• Ongoing engagement with the U.S. Federal Trade Commission (FTC) in response to its request for additional information regarding the proposed acquisition by Alcon.

Stakeholder Impact

• Shareholders: Potential for stock price decline if the Alcon merger is not consummated. Uncertainty regarding the merger's closing date.
• Employees: Potential impact on retention and hiring of key personnel due to the pending merger.
• Customers (Surgeons): Continued positive feedback and increased value through higher efficiencies and excellent patient outcomes from ALLY systems.
• Regulatory Authorities (FTC): Ongoing collaboration and response to requests for additional information regarding the Alcon merger.

Next Steps

• Continue working collaboratively with the U.S. Federal Trade Commission regarding the Alcon acquisition.
• Respond to the FTC's request for additional information.
• Work towards closing the Alcon transaction in the first quarter of 2026.
• File the Quarterly Report on Form 10-Q for the period ended September 30, 2025, with the SEC.

Key Dates

Recommendation

The company shows strong operational growth in installed base and procedure volume, indicating market acceptance of its ALLY system. However, the significant increase in net loss and negative cash flow, largely driven by acquisition-related costs, raises financial concerns. The delay in the Alcon acquisition introduces uncertainty, but the acquisition itself, if completed, could provide a significant premium and strategic benefits. Given the mixed operational performance, the financial strain, and the pending, albeit delayed, acquisition, a 'hold' recommendation is appropriate. Investors should await further clarity on the Alcon transaction and monitor cash burn.

Keywords

LENSAR, LNSR, ALLY System, Cataract Laser, Robotic Surgery, Ophthalmology, Medical Technology, Alcon Acquisition, SEC Filing, Financial Results, Q3 2025, Revenue, Net Loss, Installed Base, Procedure Volume, FTC